-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga·07/13/2026 14:10:59
语音播报
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $100 to $85.